ADAR and gastric cancer: Since two pioneering reports introduced the impact of ADAR1 on gastric cancer progression [13, 14], others have reported targets including antizyme inhibitor 1 (AZIN1) [15], the mTOR/p70S6K pathway [16], and phosphatase and actin regulator 4 (PHACTR4) [17].